![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
![[up]](/style/images/multi_up.png)
Up a levelNumber of items: 1.
AIHTA Appraisal Board Author Group, HTA Austria (2025): Lifileucel (AMTAGVI®) for previously treated unresectable or metastatic melanoma. Decision Support Document for the Austrian Appraisal Board 004.
AIHTA Appraisal Board Author Group, HTA Austria (2025): Lifileucel (AMTAGVI®) for previously treated unresectable or metastatic melanoma. Decision Support Document for the Austrian Appraisal Board 004.